Analysts' Actions: JNPR ADSK CMI DVN CNQR

TheStreet.com

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Autodesk ADSK downgraded at Jefferies to Hold from Buy, Jefferies said. $34 price target. Weaker data and limited uplift from suites. Hold rating.

Adtran ADTN upgraded at Mizuho to Buy, Mizuho said. $22 price target. Business will likely bottom out in the fourth quarter.

Cummins CMI upgraded at BMO from Market Perform to Outperform, BMO Capital said. $120 price target. Global growth appears to be stabilizing.

Concur CNQR downgraded at Piper from Neutral to Underweight, Piper Jaffray said. Valuation call, based on a $49 price target.

Devon Energy DVN downgraded at UBS to Neutral from Buy, UBS said. $60 price target. Long term outlook dims.

Devon Energy downgraded at Citigroup. DVN was downgraded to Neutral from Buy, Citigroup said. $62 price target. Lower costs, but reining in production growth outlook.

Exelon EXC upgraded at UBS to Neutral from Sell, UBS said. $30 price target. Shares now reflect a lower dvidend.

FirstMerit FMER upgraded at Baird from Underperform to Neutral, Robert Baird said. Valuation call, based on a $13 price target.

Health Net HNT upgraded at BMO from Underperform to Market Perform, BMO Capital said. $23 price target. Near-term visibility is improving.

Juniper JNPR upgraded at Cantor from Hold to Buy, Cantor Fitzgerald said. $21 price target. Company is cutting costs and is leveraged to higher carrier spending.

Linear Technology LLTC upgraded at UBS to Buy from Neutral, UBS said. $38 price target. Improved relative growth rate supports raised valuation.

Universal Display PANL downgraded at Wedbush from Outperform to Neutral, Wedbush said. $20 price target. Estimates also cut, as the company has reduced visibility.

Parker Hannifin PH upgraded at BMO to Outperform, BMO Capital said. Valuation call, based on a $94 price target.

Perrigo PRGO downgraded at Caris from Buy to Above Average, Caris & Co. said. $129 price target. Company is seeing slower demand for consumer healthcare and nutritionals.

PSS World Medical PSSI downgraded at UBS to Neutral from Buy, UBS said. $29 price target. 10Q reveals inline results.

Transocean RIG upgraded at Argus from Hold to Buy, Argus said. $62 price target. Company has made several smart strategic decisions.

Rosetta Resources ROSE upgraded at Citigroup to Buy from Neutral, Citigroup said. $60 price target. Solid Q3 beat and 2013 guidance.

Seattle Genetics SGEN downgraded at Cantor from Hold to Sell, Cantor FItzgerald said. $20 price target. Adcetris is growing slower than expected.

STOCK COMMENTS / EPS CHANGES

Accretive Health AH numbers lowered at OppenheimerShares of AH now seen reaching $15, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.

Auxilium Pharma AUXL numbers lowered at Jefferies. Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.

Cablevision CVC estimates, target reduced at Morgan Stanley. Shares of CVC now seen reaching $15, according to Morgan Stanley. Estimates also cut, as the company is realizing lower margins. Underweight rating.

HollyFrontier HFC numbers increased at Credit Suisse. HFC estimates were raised through 2015, Credit Suisse said. Company is seeing higher refining growth. Neutral rating and new $53 price target.

Melco Crown MPEL numbers raised at Citigroup. Shares of MPEL now seen reaching $22.50, Citigroup said. Estimates also increased on Q3 beat. Buy rating.

NYSE Euronext NYX numbers cut at Citigroup. Shares of NYX now seen reaching $25, Citigroup said. Estimates also lowered as environment remains challenging. Neutral rating.

RealPage RP estimates, target reduced at Credit Suisse. Shares of RP now seen reaching $27, according to Credit Suisse. Estimates also cut, gvien product delays. Outperform rating.

WellPoint WLP target raised at Jefferies. Shares of WLP now seen reaching $64, Jefferies said. Results show signs of stability. Hold rating.

WellPoint numbers lowered at Oppenheimer. Shares of WLP now seen reaching $73, Oppenheimer said. Estimates also lowered on 3Q results. Outperform rating.

Wellpoint estimates, target boosted at BMO. Shares of WLP now seen reaching $65, according to BMO Capital. Estimates also upped, as the company is keeping a tight lid on costs.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE. Sign up today to get e-mail alerts before every trade.

View Comments